

1 **Validation of a new automated chemiluminescent anti-SARS-CoV-2 IgM and IgG**
2 **antibody assay system detecting both N and S proteins in Japan**

3 Rin Yokoyama¹, Makoto Kurano^{1,2*}, Yoshifumi Morita¹, Takuya Shimura¹, Yuki Nakano¹,
4 Chungen Qian³, Fuzhen Xia⁴, Fan He⁴, Yoshiro Kishi⁵, Jun Okada⁵, Naoyuki Yoshikawa¹,
5 Yutaka Nagura⁶, Hitoshi Okazaki⁶, Kyoji Moriya⁷, Yasuyuki Seto⁸, Tatsuhiko Kodama⁹, and
6 Yutaka Yatomi^{1,2*}

7 ¹Department of Clinical Laboratory, the University of Tokyo Hospital, Tokyo, Japan

8 ²Department of Clinical Laboratory Medicine, Graduate School of Medicine, the University of
9 Tokyo, Tokyo, Japan

10 ³The Key Laboratory for Biomedical Photonics of MOE at Wuhan National Laboratory for
11 Optoelectronics - Hubei Bioinformatics & Molecular Imaging Key Laboratory, Systems
12 Biology Theme, Department of Biomedical Engineering, College of Life Science and
13 Technology, Huazhong University of Science and Technology, Hubei, P.R. China

14 ⁴Reagent R&D Center, Shenzhen YHLO Biotech Co., Ltd, Guangdong, P.R. China

15 ⁵Business Planning Department, Sales & Marketing Division, Medical & Biological
16 Laboratories Co., Ltd, Tokyo, Japan

17 ⁶Department of Blood Transfusion, the University of Tokyo Hospital, Tokyo, Japan

18 ⁷Department of Infection Control and Prevention, The University of Tokyo, Tokyo, Japan

19 ⁸Department of Gastrointestinal Surgery, The University of Tokyo, Japan

20 ⁹Laboratory for Systems Biology and Medicine, The University of Tokyo, Tokyo, Japan

21

22 *Corresponding author

23 E-mail: kurano-tyk@umin.ac.jp (M.K.) and yatoyuta-tyk@umin.ac.jp (Y.Y.)

24 **Running Title:** Anti-SARS-CoV-2 IgM and IgG tests in Japan

25 **Address correspondence to:**

26 Makoto Kurano, MD, PhD and Yutaka Yatomi, MD, PhD

27 Department of Clinical Laboratory Medicine, Graduate School of Medicine,

28 The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655, Japan

29 Tel: +81-3-3815-5411;

30 Fax: +81-3-5689-0495;

31 e-mail: kurano-tyk@umin.ac.jp (M.K.), yatoyuta-tyk@umin.ac.jp (Y.Y)

32

33

34 **Abbreviations:** AU, arbitrary unit; CLIA, chemiluminescence immunoassay; COVID-19,
35 coronavirus disease 2019; CV, coefficient variation; dsDNA, double-strand DNA; FDA, the
36 Food and Drug Administration; IgG, immunoglobulin G; IgM, immunoglobulin M; M2,
37 mitochondrial M2; N protein, Nucleocapsid protein; P-ANCA, myeloperoxidase antineutrophil
38 cytoplasmic antibody; RF, rheumatoid factor; RLU, relative light units; SARS-CoV-2, severe
39 acute respiratory syndrome coronavirus 2; SD, standard division; S protein, Spike protein; SS-A,
40 Sjögren's syndrome A
41

42 **Abstract**

43 PCR methods are presently the standard for the diagnosis of Coronavirus disease 2019
44 (COVID-19), but additional methodologies are needed to complement PCR methods, which
45 have some limitations. Here, we validated and investigated the usefulness of measuring serum
46 antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) using the
47 iFlash3000 CLIA analyzer. We measured IgM and IgG titers against SARS-CoV-2 in sera
48 collected from 26 PCR-positive COVID-19 patients, 53 COVID-19-suspected but
49 PCR-negative patients, and 20 and 100 randomly selected non-COVID-19 patients who visited
50 our hospital in 2020 and 2017, respectively. The within-day and between-day precisions were
51 regarded as good, since the coefficient variations were below 5%. Linearity was also considered
52 good between 0.6 AU/mL and 112.7 AU/mL for SARS-CoV-2 IgM and between 3.2 AU/mL and
53 55.3 AU/mL for SARS-CoV-2 IgG, while the linearity curves plateaued above the upper
54 measurement range. We also confirmed that the seroconversion and no-antibody titers were over
55 the cutoff values in all 100 serum samples collected in 2017. These results indicate that this
56 measurement system successfully detects SARS-CoV-2 IgM/IgG. We observed four
57 false-positive cases in the IgM assay and no false-positive cases in the IgG assay when 111
58 serum samples known to contain autoantibodies were evaluated. The concordance rates of the
59 antibody test with the PCR test were 98.1% for SARS-CoV-2 IgM and 100% for IgG among

60 PCR-negative cases and 30.8% for SARS-CoV-2 IgM and 73.1% for SARS-CoV-2 IgG among

61 PCR-positive cases. In conclusion, the performance of this measurement system is sufficient for

62 use in laboratory testing.

63

64 **Introduction**

65 In December 2019, the first pneumonia cases caused by an unknown microorganism
66 were identified in Wuhan, China.[1] The pathogen was identified as a novel betacoronavirus and
67 was named “severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).” [2]
68 SARS-CoV-2 is phylogenetically similar to SARS-CoV, which caused outbreaks of a severe
69 respiratory syndrome in China in 2002.[3] The symptoms of coronavirus disease 2019
70 (COVID-19), which is the respiratory syndrome caused by SARS-CoV-2, are fever, cough and
71 lymphopenia.[4] Chest computed tomography examinations of COVID-19 patients are
72 characterized by the bilateral distribution of patchy shadows or ground-glass opacities.[5] Since
73 early December 2019 and as of June 15, 2020, over 7,800,000 cases of COVID-19 have been
74 confirmed and 430,000 deaths have been reported throughout the world,[6] and the World
75 Health Organization has reported a fatality rate for cases defined as pneumonia of
76 approximately 2%.[7]

77 Currently, COVID-19 is diagnosed by the clinical presentation of the patient, as
78 described above, and the detection of SARS-CoV-2 RNA in respiratory specimens, such as a
79 nasal swab or sputum, using real-time reverse-transcription polymerase chain reaction
80 (RT-PCR).[8,9] However, this method requires skilled technicians who know how to handle
81 genetic samples and perform PCR tests and occasionally causes false-negative results because

82 of the viral replication window, a low viral titer, or incorrect sample collection.[10] Moreover,
83 the sampling of respiratory specimens exposes medical staff to a higher risk of secondary
84 infection through aerosolization than the sampling of sera.[11,12] Therefore, other methods are
85 required to complement PCR testing.

86 Candidate complementary tests include both antigen and antibody tests. Regarding
87 antigen tests, although this method does not require special skills for performing genetic testing,
88 there remains a high risk of secondary infection during sampling, and the sensitivity of antigen
89 tests is reportedly lower than that of PCR testing.[13,14] Antibody tests are another candidate.
90 Compared with PCR testing, this serological test method has a faster turn-around time and
91 requires easier and safer sample collection and less specialized skills for technicians;
92 furthermore, when we interpret the results of an antibody testing considering the duration after
93 the onset of COVID-19, this test would give us important information in diagnosing COVID-19.
94 The main concern regarding antibody tests is the high frequency of false-positive cases, which
95 is a parameter that should depend on the quality of the test product.[15,16] Recently, Shenzhen
96 YHLO Biotech Co., Ltd (China) has developed an antibody test with a high specificity[17–19];
97 however, this method has not yet been validated in the Japanese population. Therefore, in the
98 present study, we aimed to validate the measurement of IgM and IgG antibodies against
99 SARS-CoV-2 in sera and to investigate the usefulness of this method for the diagnosis of

100 COVID-19.

101

102 **Materials and Methods**

103 **Subjects**

104 We enrolled a total of 26 COVID-19-positive cases and 53 COVID-29-suspected cases
105 who were hospitalized at The University of Tokyo Hospital. Confirmed COVID-19 cases were
106 defined based on the guidelines of The University of Tokyo Hospital. Briefly, patients with
107 acute respiratory infection syndrome accompanied by detectable SARS-CoV-2 RNA in a throat
108 swab or sputum at least once were confirmed as having COVID-19 (PCR-positive cases).
109 Suspected patients were defined as subjects with respiratory symptoms, a history of overseas
110 travel, or a high-risk contact with a confirmed COVID-19 case but with negative PCR results.
111 We collected residual sera available after routine clinical testing and kept it frozen until
112 measurement. The serological tests were performed using the sample that had been collected on
113 the day closest to the day on which the sample for the PCR test had been collected. As control
114 groups, we randomly selected 20 and 100 outpatients who had visited The University of Tokyo
115 Hospital in March 2020 or January-December 2017, respectively. We also corrected 111 serum
116 samples known to contain autoantibodies.

117 The current study was performed in accordance with the Declaration of Helsinki.
118 Informed consent was obtained in the form of an opt-out form on the institution's website. This
119 study was conducted with the approval of The University of Tokyo Medical Research Center
120 Ethics Committee (2019300NI-3).

121 **Antibody testing**

122 Antibody testing was performed using SARS-CoV-2 IgM and IgG chemiluminescence
123 immunoassay (CLIA) kits supplied by Shenzhen YHLO Biotech Co., Ltd. (China) and an
124 iFlash3000 fully automated CLIA analyzer also from Shenzhen YHLO Biotech Co., Ltd.
125 (China). Two antigens of SARS-CoV-2 (nucleocapsid protein [N protein] and spike protein [S
126 protein]) were coated on the magnetic beads of these CLIA assays. The SARS-CoV-2 IgM or
127 IgG titers were calculated as relative light units (RLU) obtained from the analyzer and were
128 described as arbitrary units per milliliter (AU/mL). According to the manufacturer's instructions,
129 the cutoff value for a positive SARS-CoV-2 IgM/IgG result was deemed as 10 AU/mL. If the
130 SARS-CoV-2 IgG titer was over 40 AU/mL, the sample was diluted with non-reactive serum
131 and the antibody titers were measured once again.

132 **Method validation**

133 The within-day precision was validated by measuring 3 kinds of serum samples with

134 20 replications simultaneously. Then, we calculated the mean value, the standard deviation (SD),
135 and the coefficient of variation (CV) for each sample. The between-day precision was validated
136 using two kinds of quality-control samples provided by the manufacturer. These samples were
137 measured twice a day on days 0, 1, 2, 3, 4, 5, 9-11, and 16. Linearity was investigated using two
138 kinds of pooled serum samples. Briefly, each sample was diluted with pooled non-reactive
139 serum in two-fold serial dilutions for ten times. To investigate the existence of the prozone
140 phenomenon, we diluted the samples with high concentrations of SARS-CoV-2 IgM and IgG
141 titers using ten-fold serial dilutions for the SARS-CoV-2 IgM assay and two-fold serial dilutions
142 for the SARS-CoV-2 IgG assay.

143 **Statistical analysis**

144 The data were analyzed using StatFlex software (Osaka, Japan). The results were
145 expressed as the mean \pm SD. The Dunn test was used for comparisons of antibody titers
146 between the control and other groups. A value of $p < 0.05$ was regarded as statistically
147 significant in all the analyses.

148

149 **Results**

150 **Precision and accuracy of antibody testing**

151 First, we investigated the precision and accuracy of the antibody testing. As shown in
152 Table 1A, the intra-day precision values were 1.9%-2.9% for SARS-CoV-2 IgM and 1.1%-3.3%
153 for SARS-CoV-2 IgG, while the between-day precision values were 1.9%-3.3% for
154 SARS-CoV-2 IgM and 2.5%-3.7% for SARS-CoV-2 IgG.

155

156 **Table 1. Within-day and between-day precision of SARS-CoV-2 IgM/IgG titers**

A. Within-day precision				
	Sample	Mean (AU/mL)	SD (AU/mL)	CV (%)
SARS-CoV-2 IgM	1	2.0	0.04	2.03
	2	7.0	0.13	1.86
	3	83.8	2.46	2.94
SARS-CoV-2 IgG	4	3.7	0.06	1.68
	5	10.2	0.11	1.06
	6	74.3	2.47	3.32

B. Between-day precision				
	Sample	Mean (AU/mL)	SD (AU/mL)	CV (%)
SARS-CoV-2 IgM	1	3.8	0.13	3.31
	2	15.9	0.30	1.90
SARS-CoV-2 IgG	3	5.1	0.13	2.53

4	17.5	0.64	3.67
---	------	------	------

157 (A) Within-day precision. We measured SARS-CoV-2 IgM and IgG in three kinds of samples;
158 each sample was analyzed with 20 replicates on the same day. (B) Between-day precision.
159 We continuously measured two kinds of samples on days 0, 1, 2, 3, 4, 5, 9-11, and 16; each
160 sample was analyzed with 2 replicates.

161

162 **Measurement range of SARS-CoV-2 antibody testing**

163 To explore the measurement range of this antibody test, we performed a linear
164 regression analysis. When we investigated linearity using samples with moderate antibody titers,
165 the curves showed a good linearity between 0.6 AU/mL and 112.7 AU/mL for SARS-CoV-2
166 IgM and between 3.2 AU/mL and 55.3 AU/mL for SARS-CoV-2 IgG (Fig. 1). Next, we
167 measured samples with high antibody titers to determine the upper limit of the measurement
168 range. In the SARS-CoV-2 IgM assay, the upper curve increased up to a value of 2,405 AU/mL
169 and then reached a plateau at higher concentrations. In the SARS-CoV-2 IgG assay, the curve
170 reached a plateau at values over 73 AU/mL (Fig. 2). Therefore, we diluted the samples and
171 determined the SARS-CoV-2 IgG titers for SARS-CoV-2 IgG levels over 50 AU/mL. In both
172 assays, a hook effect was not observed.

173

174 **Fig 1. Linearity analyses of SARS-CoV-2 antibody titer.**

175 The dilution linearities of SARS-CoV-2 IgM (A, B) and SARS-CoV-2 IgG (C, D) were
176 investigated. A sample was diluted with non-reactive serum in 5 to 8 steps; each sample was
177 then analyzed with two replicates.

178

179 **Fig 2. Prozone phenomena of SARS-CoV-2 antibody titer.**

180 The prozone phenomena of SARS-CoV-2 IgM (A) and SARS-CoV-2 IgG (B) were investigated.
181 We diluted two serum samples from infected patients with non-reactive serum in 10 steps; each
182 sample was then analyzed with two replicates.

183

184 **Successful detection of SARS-CoV-2 IgM/IgG**

185 To confirm that this antibody measurement system could detect SARS-CoV-2
186 IgM/IgG successfully, we measured the antibody titers in sera obtained before and after
187 infection with SARS-CoV-2 in three cases of COVID-19 confirmed using RT-PCR tests. As
188 shown in Fig. 3, SARS-CoV-2 IgM and IgG were not detected before symptom onset; at several
189 days after symptom onset, tests for both antibodies became positive and the titers gradually
190 increased. In case 1, the IgM test once again became negative 19 days after hospitalization.

191 Second, we obtained 100 random serum samples collected from outpatients who had
192 visited The University of Tokyo Hospital in 2017, when SARS-CoV-2 did not exist. None of
193 these samples had an antibody titer over 10 AU/mL, suggesting that this measurement system
194 can detect SARS-CoV-2 IgM/IgG without false-positive results (Fig. 4).

195

196 **Fig 3. Time course of serum antibody titers in COVID-19 subjects.**

197 The time courses of the SARS-CoV-2 IgM and SARS-CoV-2 IgG titers in sera collected before
198 and after the onset of COVID-19 were examined in three patients.

199

200 **Fig 4. Serum antibody titers in sera from 2017.**

201 The SARS-CoV-2 IgM/IgG titers of sera collected from subjects (n = 100) in 2017 were
202 measured.

203

204 **Cross-reactivity with autoantibodies**

205 Since the presence of autoantibodies can sometimes affect the results of serological
206 tests, we measured SARS-CoV-2 IgM/IgG in residual serum samples collected from patients

207 with one of 5 different autoimmune diseases. For IgM, most of the serum samples from the
208 patients with autoimmune diseases did not have a result over 10 AU/mL. However, two
209 rheumatoid factor-positive patients, one anti-double-strand DNA antibody-positive patient, and
210 one anti-mitochondrial M2 antibody-positive patient had values that exceeded the cutoff value
211 (Fig. 5A). For IgG, none of the autoantibody-positive serum samples had a result that was over
212 10 AU/mL (Fig. 5B).

213

214 **Fig 5. Interference from autoantibodies in SARS-CoV-2 IgM/IgG assay.**

215 We collected sera from patients with autoimmune diseases and measured the SARS-CoV-2 IgM
216 (A) and IgG (B) titers. * $p < 0.05$, ** $p < 0.01$. Control, randomly selected outpatients who
217 visited the hospital in 2020 (n = 20); RF, rheumatoid factor-positive group (n = 25); dsDNA,
218 anti-double-strand DNA antibody-positive group (n = 26); M2, anti-mitochondrial M2
219 antibody-positive group (n = 20); P-ANCA, myeloperoxidase antineutrophil cytoplasmic
220 antibody-positive group (n = 20); SS-A, anti-Sjögren's syndrome A antibody-positive group (n =
221 20); Suspected, suspected COVID-19 group (n = 53); Positive, COVID-19-positive group (n =
222 26).

223

224 **Concordance rate with PCR testing**

225 To investigate clinical usefulness, we compared the results of the serological antibody
226 tests with those of PCR tests. Among the 26 PCR-positive COVID-19 cases, 8 cases (30.8%)
227 had IgM-positive results and 19 cases (73.1%) had IgG-positive results. Among the 53
228 PCR-negative COVID-19-suspected cases, 52 cases (98.1%) had IgM levels below 10 AU/mL
229 and all the cases (100%) had IgG levels below 10 AU/mL (Table 2).

230

231 **Table 2. Concordance rate between the results of PCR testing and SARS-CoV-2 IgM or**
232 **IgG serological testing**

	SARS-CoV-2 PCR test	
	positive cases (n = 26)	negative cases (n = 53)
SARS-CoV-2 IgM >10 AU/mL	8 (30.8%)	1
≤10 AU/mL	18	52 (98.1%)

	SARS-CoV-2 PCR test	
	positive cases (n =	negative cases (n =

		26)	53)
SARS-CoV-2 IgG	>10 AU/mL	19 (73.1%)	0
	≤10 AU/mL	7	53 (100%)

233 We measured SARS-CoV-2 IgM and IgG in PCR-positive subjects (n = 26) and PCR-negative
234 subjects (n = 53). An antibody titer above 10 AU/mL was regarded as positive, according to the
235 manufacturer's cutoff.

236

237 **Suspected false-positive IgM results might be caused by reactivity to N protein**

238 In this study, we observed 5 suspected false-positive IgM results. As described in the
239 *Materials and Methods* section, the measurement system tests the reactivity to both the N
240 protein and the S protein of SARS-CoV-2. We investigated the reactivity of the samples to N
241 protein and S protein separately, and only reactivity to N protein was observed in the 5
242 suspected false-positive samples (Table 3).

243

244 **Table 3. IgM reactivity to N protein and S protein in subjects with suspected false-negative**

245 **IgM results**

Sample	S+N protein (AU/mL)	N protein (AU/mL)	S protein (AU/mL)
--------	---------------------	-------------------	-------------------

1	53.76	97.17	0.34
2	16.43	18.14	0.96
3	13.03	10.51	0.34
4	17.94	29.31	0.69
5	110.11	130.57	1.15

246 We investigated the IgM reactivity to N protein and S protein in five subjects with suspected
247 false-negative IgM results. N or S protein means the value measured using magnetic beads
248 coated with either antigen, respectively.

249

250 Discussion

251 In this study, we validated a method for quantifying SARS-CoV-2 IgM and IgG using
252 the iFlash3000 automated CLIA analyzer. First, the within-day precisions of the SARS-CoV-2
253 IgM and IgG assays were obviously good in validations using three kinds of serum samples: a
254 sample with a negative antibody titer, a sample with a titer close to the cutoff level, and an
255 obviously positive sample (Table 1A). The between-day precisions for both assays also seemed
256 good (Table 1B). These results suggest that relatively stable data were provided by this
257 measurement system, while some anti-SARS-CoV-2 antibody detection kits authorized for
258 emergency use by the Food and Drug Administration (FDA) in the USA have a CV of more than

259 5% for within-day precision and some manufacturers do not even publish precision data for
260 their products. The linearity was good up to values of 112.7 AU/mL for SARS-CoV-2 IgM and
261 55.3 AU/mL for IgG, while the assay signal gradually reached a plateau at over 2,405 AU/mL
262 for SARS-CoV-2 IgM and over 73 AU/mL for IgG (Fig. 2). Therefore, the sample should be
263 diluted if the measured value is expected to be higher than the measurement range. To dilute
264 samples, non-reactive serum should be used as a diluent, since the titers are calculated as values
265 lower than the actual values when saline is used as a diluent, especially for IgM measurements
266 (data not shown). Clinical decisions are rarely affected by this phenomenon, since the
267 measurement range that was validated in the present study covers much higher values than the
268 manufacturer's cutoff.

269 Regarding the antibody tests, in addition to issues surrounding accuracy, the matter of
270 false-positive cases has also been a concern. As shown in Fig. 3, the SARS-CoV-2 IgM/IgG
271 levels were negative before hospitalization in three cases, and these antibody levels
272 subsequently became positive after symptom onset in all cases, suggesting that this serological
273 test can surely detect antibodies against SARS-CoV-2. In addition, we demonstrated that this
274 measurement system could detect SARS-CoV-2 IgM/IgG without any false-positive results by
275 evaluating 100 serum samples collected in 2017, when SARS-CoV-2 did not exist. These results
276 confirm that this measurement system might be able to detect antibodies against SARS-CoV-2

277 alone, without cross-reactivity with other coronavirus strains that cause 15%-29% of all
278 common colds.[20,21] Chemiluminescence immunoassays are known to be affected by
279 autoantibodies, such as rheumatoid factor, relatively often.[22] In the present study, we
280 investigated whether five kinds of autoantibodies might interfere with the measurement system
281 and found that no false-positive results were observed for the IgG assays, while four
282 false-positive cases were observed for the IgM assays. We also found one PCR-negative case
283 with a SARS-CoV-2 IgM titer over the cutoff value. Actually, when we investigated the
284 reactivity of N protein and S protein to the sera separately, we found that the false-positive cases
285 were caused by reactivity to the N protein (Table 3). The reason for this reactivity remains
286 unclear at present but might be due to the cross-reactivity of the measurement system or, since
287 the structure of the N protein of SARS-CoV-2 is similar to that of other coronavirus strains,
288 antibodies to a structure similar to the N protein of SARS-CoV-2 might actually exist.

289 Finally, we investigated the concordance rate between PCR and this measurement
290 system. As shown in Table 2, although all the PCR-negative subjects had negative results except
291 for one subject with a high IgM level, the PCR-positive subjects did not necessarily have
292 positive results for IgM or IgG. This discrepancy might be due to the fact that we used the
293 serum sample that had been collected on the day nearest to the day on which the PCR sample
294 had been collected. In several cases, only a few days had passed since the onset of symptoms,

295 and IgG and IgM are reportedly not detectable during the early phase of COVID-19.[23]
296 Therefore, the time course for the appearance of IgG and IgM must be investigated for the
297 application of antibody tests in clinical practice.

298 A characteristic of the present method is that both the N protein and the S protein are
299 used as antigens. Reportedly, the sensitivity and specificity might depend on the types of
300 antigens that are recognized by the antibodies, and the antibody to S protein is more sensitive
301 than the antibody to N protein.[24–26] Since the measurement system in the present study uses
302 both the S and N proteins, this system might provide a greater sensitivity and diagnostic ability
303 than an antibody test using either the S protein or the N protein alone. In contrast, analyzing the
304 reactivity to both proteins could increase the number of false-positive cases, as described above.
305 Further studies on the clinical significances of antibodies to N protein and S protein might be
306 necessary to conclude which is most appropriate: measuring the reactivity to both proteins or to
307 each protein separately.

308 In conclusion, we have validated a measurement system for detecting IgM and IgG
309 against SARS-CoV-2 using CLIA kits and have observed that this system had sufficient
310 performance for its introduction into clinical laboratory testing. Moreover, the possibility of
311 false-negative results, especially for IgG against SARS-CoV-2, was relatively low. In the future,
312 this method might be helpful for clinical diagnosis, epidemiological investigations, and the

313 development of vaccines.

314

315 **Acknowledgements**

316 We are thankful to the Murakami Foundation for the donation of the iFlash3000 to The

317 University of Tokyo Hospital.

318

319 **Funding Sources**

320 None.

321

322 **Authorship Contributions**

323 R.Y. participated in experiments and the data analysis and drafted the initial manuscript, Y.N.,

324 Y.M., T.S., Y.N., and N.Y. participated in the experiments. M.K. participated in the study design,

325 data analysis, helped to draft the manuscript, and conceived the study. C.Q., F. X., F. H., Y. K.

326 and J. O. developed the antibody measurement system. H.O., K.M., and Y.S. participated in the

327 discussion and helped to draft the manuscript. T.K. and Y.Y. conceived the study, coordinated

328 the study design, and helped to draft the manuscript. All the authors have read and approved the

329 final manuscript.

330

331 **Disclosure of Conflicts of Interest**

332 The present study is a collaborative research project among The University of Tokyo, Shenzhen
333 YHLO Biotech Co., Ltd, and Medical & Biological Laboratories Co., Ltd. F. X. and F. H. are
334 employees of Shenzhen YHLO Biotech Co., Ltd and Y. K. and J. O. are employees of Medical
335 & Biological Laboratories Co., Ltd.

336

337 **Data Availability Statement**

338 The datasets generated or analyzed in the current study are available upon reasonable
339 request.

340

341 **References**

- 342 1. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients
343 infected with 2019 novel coronavirus in Wuhan, China. *Lancet*. 2020;395: 497–506.
344 doi:10.1016/S0140-6736(20)30183-5
- 345 2. Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, et al. Genomic characterisation and

- 346 epidemiology of 2019 novel coronavirus: implications for virus origins and receptor
347 binding. *Lancet*. 2020;395: 565–574. doi:10.1016/S0140-6736(20)30251-8
- 348 3. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A novel coronavirus from
349 patients with pneumonia in China, 2019. *N Engl J Med*. 2020;382: 727–733.
350 doi:10.1056/NEJMoa2001017
- 351 4. Guan W, Ni Z, Hu Y, Liang W, Ou C, He J, et al. Clinical Characteristics of Coronavirus
352 Disease 2019 in China. *N Engl J Med*. 2020;382: 1708–1720.
353 doi:10.1056/NEJMoa2002032
- 354 5. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical Characteristics of 138
355 Hospitalized Patients with 2019 Novel Coronavirus-Infected Pneumonia in Wuhan,
356 China. *JAMA - J Am Med Assoc*. 2020;323: 1061–1069. doi:10.1001/jama.2020.1585
- 357 6. World Health Organization. Coronavirus disease (COVID-19) Situation Report-147.
358 Available from: <https://apps.who.int/iris/handle/10665/332550>
- 359 7. World Health Organization. Coronavirus disease 2019 (COVID-19) Situation Report–36.
360 Available from: <https://apps.who.int/iris/handle/10665/331222>
- 361 8. World Health Organization. Laboratory testing for coronavirus disease 2019
362 (COVID-19) in suspected human cases: interim guidance, 2 March 2020. 2020.

- 363 Available from: <https://apps.who.int/iris/handle/10665/331329>
- 364 9. Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, et al. Early Transmission Dynamics in
365 Wuhan, China, of Novel Coronavirus–Infected Pneumonia. *N Engl J Med.* 2020;382:
366 1199–1207. doi:10.1056/NEJMoa2001316
- 367 10. Yang Y, Yang M, Shen C, Wang F, Yuan J, Li J, et al. Evaluating the accuracy of
368 different respiratory specimens in the laboratory diagnosis and monitoring the viral
369 shedding of 2019-nCoV infections. *medRxiv [Preprint]. Cold Spring Harbor Laboratory*
370 *Press*; 2020. p. 2020.02.11.20021493. doi:10.1101/2020.02.11.20021493
- 371 11. Kim J-M, Kim HM, Lee EJ, Jo HJ, Yoon Y, Lee N-J, et al. Detection and Isolation of
372 SARS-CoV-2 in Serum, Urine, and Stool Specimens of COVID-19 Patients from the
373 Republic of Korea. *Osong Public Heal Res Perspect.* 2020;11: 112–117.
374 doi:10.24171/j.phrp.2020.11.3.02
- 375 12. Wölfel R, Corman VM, Guggemos W, Seilmaier M, Zange S, Müller MA, et al.
376 Virological assessment of hospitalized patients with COVID-2019. *Nature.* 2020;581:
377 465–469. doi:10.1038/s41586-020-2196-x
- 378 13. Porte L, Legarraga P, Vollrath V, Aguilera X, Munita JM, Araos R, et al. Evaluation of
379 novel antigen-based rapid detection test for the diagnosis of SARS-CoV-2 in respiratory

- 380 samples. *Int J Infect Dis* [Preprint]. 2020 [cited 28 Jun 2020].
- 381 doi:10.1016/j.ijid.2020.05.098
- 382 14. Scohy A, Anantharajah A, Bodéus M, Kabamba-Mukadi B, Verroken A,
- 383 Rodriguez-Villalobos H. Low performance of rapid antigen detection test as frontline
- 384 testing for COVID-19 diagnosis. *J Clin Virol*. 2020;129. doi:10.1016/j.jcv.2020.104455
- 385 15. Wang Q, Du Q, Guo B, Mu D, Lu X, Ma Q, et al. A Method To Prevent SARS-CoV-2
- 386 IgM False Positives in Gold Immunochromatography and Enzyme-Linked
- 387 Immunosorbent Assays. *J Clin Microbiol*. 2020;58. doi:10.1128/JCM.00375-20
- 388 16. Li Z, Yi Y, Luo X, Xiong N, Liu Y, Li S, et al. Development and Clinical Application of
- 389 A Rapid IgM-IgG Combined Antibody Test for SARS-CoV-2 Infection Diagnosis. *J*
- 390 *Med Virol*. 2020; jmv.25727. doi:10.1002/jmv.25727
- 391 17. Infantino M, Grossi V, Lari B, Bambi R, Perri A, Manneschi M, et al. Diagnostic
- 392 accuracy of an automated chemiluminescent immunoassay for anti-SARS-CoV-2 IgM
- 393 and IgG antibodies: an Italian experience. *J Med Virol*. 2020; 1–5.
- 394 doi:10.1002/jmv.25932
- 395 18. Dong L, Tian J, He S, Zhu C, Wang J, Liu C, et al. Possible Vertical Transmission of
- 396 SARS-CoV-2 from an Infected Mother to Her Newborn. *JAMA - Journal of the*

- 397 American Medical Association. American Medical Association; 2020. pp. 1846–1848.
- 398 doi:10.1001/jama.2020.4621
- 399 19. Zeng H, Xu C, Fan J, Tang Y, Deng Q, Zhang W, et al. Antibodies in Infants Born to
400 Mothers with COVID-19 Pneumonia. JAMA - Journal of the American Medical
401 Association. American Medical Association; 2020. pp. 1848–1849.
402 doi:10.1001/jama.2020.4861
- 403 20. Su S, Wong G, Shi W, Liu J, Lai ACK, Zhou J, et al. Epidemiology, Genetic
404 Recombination, and Pathogenesis of Coronaviruses. Trends in Microbiology. Elsevier
405 Ltd; 2016. pp. 490–502. doi:10.1016/j.tim.2016.03.003
- 406 21. Monto AS. Medical reviews. Coronaviruses. Yale J Biol Med. 1974;47: 234–51.
- 407 22. Hirano K, Maruyama S, Mino Y, Naito T, Kawakami J. Suitability of chemiluminescent
408 enzyme immunoassay for the measurement of blood tacrolimus concentrations in
409 rheumatoid arthritis. Clin Biochem. 2011;44: 397–402.
410 doi:10.1016/j.clinbiochem.2010.12.020
- 411 23. Jin Y, Wang M, Zuo Z, Fan C, Ye F, Cai Z, et al. Diagnostic value and dynamic variance
412 of serum antibody in coronavirus disease 2019. Int J Infect Dis. 2020;94: 49–52.
413 doi:10.1016/j.ijid.2020.03.065

- 414 24. Zhong L, Chuan J, Gong B, Shuai P, Zhou Y, Zhang Y, et al. Detection of serum IgM
415 and IgG for COVID-19 diagnosis. *Sci China Life Sci.* 2020;63: 777–780.
416 doi:10.1007/s11427-020-1688-9
- 417 25. Kontou PI, Braliou GG, Dimou NL, Nikolopoulos G, Bagos PG. Antibody tests in
418 detecting SARS-CoV-2 infection: A meta-analysis. *Diagnostics.* 2020;10.
419 doi:10.3390/diagnostics10050319
- 420 26. Liu W, Liu L, Kou G, Zheng Y, Ding Y, Ni W, et al. Evaluation of Nucleocapsid and
421 Spike Protein-Based Enzyme-Linked Immunosorbent Assays for Detecting Antibodies
422 against SARS-CoV-2. *J Clin Microbiol.* 2020;58. doi:10.1128/JCM.00461-20
423

Figure 1








Figure 2

A



B






Figure 3

Case 1.



Case 2.



Case 3.




Figure 4




Figure 5

